Adolescent antidepressant problem rears its head once more

29 March 2016
depression-child-large

More young people than ever are taking drugs for depression in the developed world but recent studies have come up with some disturbing findings that cast a dark shadow over their use.

One report reveals how the number of children and adolescents being prescribed antidepressants has soared since 2006 in some European countries and in the US.

Another highlights the high risk of aggression, self-harm and suicide among young people on antidepressants while suggesting that neither clinical trials nor the data they provide are not up to scratch.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical